Complix, a Belgium-based biotechnology company, has raised €5m ($6.25m) in series A funding. European venture capital firms Vesalius Biocapital (Luxembourg) and LRM (Belgium) co-led the round.
The Centre de Recherche Public de la Santé (CRP Sante), a Luxembourg-based research organisation, also funded the series A round. Complix will start a subsidiary in Luxembourg to develop novel therapies against viral diseases in a strategic collaboration with CRP Sante.